Axsome Therapeutics (AXSM) Revenue (2022 - 2026)

Axsome Therapeutics has disclosed Revenue across 5 years of filings, most recently posting $191.2 million for Q1 2026.

• Revenue for Q1 2026 came in at $191.2 million, up 57.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $708.2 million (up 125.63% YoY), and the FY2025 annual result was $638.5 million, up 65.55% from the prior year.
• Revenue came in at $191.2 million for Q1 2026 at Axsome Therapeutics, down from $196.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $196.0 million in Q4 2025 to a low of $500000.0 in Q4 2024.
• The 5-year median for Revenue is $81.1 million (2024), against an average of $88.6 million.
• Across the five-year window, Revenue slumped 99.3% in 2024 and surged 39099.8% in 2025, its largest moves.
• Axsome Therapeutics' Revenue stood at $24.4 million in 2022, then soared by 193.5% to $71.5 million in 2023, then plunged by 99.3% to $500000.0 in 2024, then soared by 39099.8% to $196.0 million in 2025, then slipped by 2.45% to $191.2 million in 2026.
• The last three Revenue figures came in at $191.2 million (Q1 2026), $196.0 million (Q4 2025), and $171.0 million (Q3 2025), per Business Quant data.